ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

ClinicalTrials.gov ID: NCT00623103

Public ClinicalTrials.gov record NCT00623103. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)

Study identification

NCT ID
NCT00623103
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novartis
Industry
Enrollment
583 participants

Conditions and interventions

Interventions

  • Rivastigmine capsule Drug
  • Rivastigmine transdermal patch Drug

Drug

Eligibility (public fields only)

Age range
50 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 31, 2007
Primary completion
Oct 31, 2010
Completion
Not listed
Last update posted
Nov 27, 2011

Started 2008

United States locations

U.S. sites
17
U.S. states
14
U.S. cities
17
Facility City State ZIP Site status
University of Alabama at Birmingham Birmingham Alabama 35233
21st Century Neurology Phoenix Arizona 85004
Neurosearch, Inc. Reseda California 91335
Neurosearch II, Inc. Ventura California 93003
Sunrise Clinical Research, Inc. Hollywood Florida 33021
Collier Neurologic Specialists Naples Florida 34102
Comprehensive Neurology Specialists, PC Suwanee Georgia 30024
Neurological Associates Meridian Idaho 83646
Evanstan Northwestern Healthcare Medical Group Glenview Illinois 60026
University of Kansas Medical Center Kansas City Kansas 66160
Neurological Care of Central NY Syracuse New York 13210-1853
Neurology & Neuroscience Associates, Inc. Akron Ohio 44302
Square 1 Clinical Research Erie Pennsylvania 16506
Research Protocol Management Solutions Pittsburgh Pennsylvania 15243
Neurology Specialists of Dallas Dallas Texas 75231
Progressive Clinical Research Bountiful Utah 84010
Veterans Affairs Puget Sound Health Care System Seattle Washington 98108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 110 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00623103, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 27, 2011 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00623103 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →